ojrdrtОнкологический журнал: лучевая диагностика, лучевая терапияJournal of oncology: diagnostic radiology and radiotherapy2587-75932713-167XНЕКОММЕРЧЕСКОЕ ПАРТНЕРСТВО «ОБЩЕСТВО ИНТЕРВЕНЦИОННЫХ ОНКОРАДИОЛОГОВ»10.37174/2587-7593-2023-6-4-99-104ojrdrt-335Research ArticleКЛИНИЧЕСКИЕ СЛУЧАИCLINICAL CASESПЭТ/КТ с 68Ga-FAPI в диагностике рака неизвестной первичной локализации. Клиническое наблюдениеPET/CT with 68Ga-FAPI in the Diagnosis of Cancer of Unknown Primary Localization. Clinical Casehttps://orcid.org/0000-0001-7226-5129ТулинП. Е.TulinP. E.

Павел Евгеньевич Тулин, к. м. н., с. н. с.

НИИ клинической и экспериментальной радиологии

отделение радионуклидной диагностики № 2

115478

Каширское шоссе, 24

Москва

115478

24 Kashirskoye Shosse

Moscow

https://orcid.org/0000-0001-5348-5011ПоляковА. Н.PolyakovA. N.

Александр Николаевич Поляков, к. м. н., с. н. с.

НИИ клинической онкологии

отделение абдоминальной онкологии № 2 (опухолей гепатопанкреатобиллиарной зоны)

115478

Каширское шоссе, 24

Москва

115478

24 Kashirskoye Shosse

Moscow

https://orcid.org/0000-0003-1632-351XПронинА. И.ProninA. I.

Артем Игоревич Пронин, к. м. н., врач-рентгенолог, заведующий отделением

НИИ клинической и экспериментальной радиологии

отделение радионуклидной диагностики № 2

115478

Каширское шоссе, 24

Москва

115478

24 Kashirskoye Shosse

Moscow

Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина Минздрава РоссииРоссияN.N. Blokhin National Medical Research Center of OncologyRussian Federation2023171220236499104Copyright © Тулин П.Е., Поляков А.Н., Пронин А.И., 20232023Тулин П.Е., Поляков А.Н., Пронин А.И.Tulin P.E., Polyakov A.N., Pronin A.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.oncoradjournal.ru/jour/article/view/335   Цель

   Цель: Провести анализ клинического случая выявления методом ПЭТ/КТ с 68Ga-FAPI первичного очага у пациентки с метастатическим поражением печени из неизвестной первичной локализации (НПО).

   Материал и методы

   Материал и методы: У больной с метастазами в печени из НПО проведен комплекс диагностических методов (КТ, МРТ, ЭГДС, ПЭТ/КТ с 18F-ФДГ), по результатам которого первичный очаг не был достоверно выявлен. ПЭТ/КТ с 68Ga-FAPI позволила выявить первичный очаг, который локализовался в левой молочной железе и не накапливал 18F-ФДГ. По данным маммографии, образование в левой молочной железе расценено как доброкачественные изменения (BI-RADS-2). По результатам гистологического исследования узел в левой молочной железе соответствовал инвазивному протоковому раку.

   Заключение

   Заключение: ПЭТ/КТ с 68Ga-FAPI потенциально может превзойти ПЭТ/КТ с 18F-ФДГ в выявлении первичной опухоли при метастазах из НПО.

   Purpose

   Purpose: Analysis of a clinical case of detection the primary focus in a patient with metastatic liver damage from cancer of unknown primary localization using PET/CT with 68Ga-FAPI.

   Material and methods

   Material and methods: A patient with metastatic liver damage from CUP underwent a set of diagnostic methods, according to the results of which the primary focus was not detected. PET/CT with 68Ga-FAPI revealed the primary focus, which was localize in the left breast and did not accumulate 18F-FDG. According to mammography, the formation in the left breast was regard as benign changes (BI-RADS-2). According to the results of histological examination, the node in the left breast is invasive ductal cancer.

   Conclusion

   Conclusion: PET/CT with 68Ga-FAPI can potentially surpass PET/CT with 18F-FDG in the detection of primary tumors in metastases from cancer of unknown primary localization.

ПЭТ/КТпозитронная эмиссионная томография68Ga-FAPI18F-ФДГметастазы в печенинеизвестная первичная локализацияPET/CTpositron emission tomography68Ga-FAPI18F-FDGliver metastasescancer of unknown primary localizationИсследование проведено без спонсорской поддержкиThe study had no sponsorshipReferencesWoo S, Becker AS, Do RK, et al. Impact of 18F-Fluorodeoxyglucose positron emission tomography on management of cancer of unknown primary: systematic review and meta-analysis. Eur J Cancer. 2021;159:60-77. DOI: 10.1016/j.ejca.2021.09.031.Woo S, Becker AS, Do RK, et al. Impact of 18F-Fluorodeoxyglucose positron emission tomography on management of cancer of unknown primary: systematic review and meta-analysis. Eur J Cancer. 2021;159:60-77. DOI: 10.1016/j.ejca.2021.09.031.Rassy E, Pavlidis N. The currently declining incidence of cancer of unknown primary. Cancer Epidemiology. 2019;61:139-41. DOI: 10.1016/j.canep.2019.06.006.Rassy E, Pavlidis N. The currently declining incidence of cancer of unknown primary. Cancer Epidemiology. 2019;61:139-41. DOI: 10.1016/j.canep.2019.06.006.Ding Y, Jiang J, Xu J, et al. Site-specific therapy in cancers of unknown primary site: a systematic review and meta-analysis. ESMO Open. 2022;7(2):100407. DOI: 10.1016/j.esmoop.2022.100407.Ding Y, Jiang J, Xu J, et al. Site-specific therapy in cancers of unknown primary site: a systematic review and meta-analysis. ESMO Open. 2022;7(2):100407. DOI: 10.1016/j.esmoop.2022.100407.Massard C, Loriot Y, Fizazi K. Carcinomas of an unknown primary origin—diagnosis and treatment. Nature reviews Clinical Oncol. 2011;8(12):701-10. DOI: 10.1038/nrclinonc.2011.158.Massard C, Loriot Y, Fizazi K. Carcinomas of an unknown primary origin—diagnosis and treatment. Nature reviews Clinical Oncol. 2011;8(12):701-10. DOI: 10.1038/nrclinonc.2011.158.Pavlidis N, Pentheroudakis G. Cancer of unknown primary site: 20 questions to be answered. Ann Oncol. 2010;21:303-7. DOI: 10.1093/annonc/mdq278.Pavlidis N, Pentheroudakis G. Cancer of unknown primary site: 20 questions to be answered. Ann Oncol. 2010;21:303-7. DOI: 10.1093/annonc/mdq278.Pavlidis N, Briasoulis E, Pentheroudakis G. Cancers of unknown primary site: ESMO Clinical Practice Guide-lines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21:228-31. DOI: 10.1093/annonc/mdq193.Pavlidis N, Briasoulis E, Pentheroudakis G. Cancers of unknown primary site: ESMO Clinical Practice Guide-lines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21:228-31. DOI: 10.1093/annonc/mdq193.Krämer A, Bochtler T, Pauli C, et al. Cancer of unknown primary: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;34(3):228-46. DOI: 10.1016/j.annonc.2022.11.013.Krämer A, Bochtler T, Pauli C, et al. Cancer of unknown primary: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;34(3):228-46. DOI: 10.1016/j.annonc.2022.11.013.Новик АВ, Гладков ОА, Имянитов ЕН и др. Практические рекомендации по лекарственному лечению опухолей невыявленной первичной локализации. Злокачественные опухоли: Практические рекомендации RUSSCO №3s2. 2022;353-65. DOI: 10.18027/2224-5057-2022-12-3s2-353-365.Novik AB, Gladkov AA, Imyanitov EN, et al. Practical recommendations for the drug treatment of tumors of undetected primary localization. Malignant tumors: Practical recommendations RUSSCO №3s2. 2022;353-65. (In Russian) DOI: 10.18027/2224-5057-2022-12-3s2-353-365.Kwee TC, Kwee RM. Combined FDG-PET/CT for the detection of unknown primary tumors: systematic review and meta-analysis. Eur Radiol. 2009;19:731-44. DOI: 10.1007/s00330-008-1194-4.Kwee TC, Kwee RM. Combined FDG-PET/CT for the detection of unknown primary tumors: systematic review and meta-analysis. Eur Radiol. 2009;19:731-44. DOI: 10.1007/s00330-008-1194-4.Riaz S, Nawaz MK, Faruqui ZS, et al. Diagnostic accuracy of 18F-fluorodeoxyglucose positron emission tomography-computed tomography in the evaluation of carcinoma of unknown primary. Mol Imaging and Radionuclide Therapy. 2016;25(1):11. DOI: 10.4274/mirt.05706.Riaz S, Nawaz MK, Faruqui ZS, et al. Diagnostic accuracy of 18F-fluorodeoxyglucose positron emission tomography-computed tomography in the evaluation of carcinoma of unknown primary. Mol Imaging and Radionuclide Therapy. 2016;25(1):11. DOI: 10.4274/mirt.05706.Haas I, Hoffmann T.K, Engers R, et al. Diagnostic strategies in cervical carcinoma of an unknown primary (CUP). Eur Archives of Otorhinolaryngol. 2002;259:325-33. DOI: 10.1007/s00405-002-0470-1.Haas I, Hoffmann T.K, Engers R, et al. Diagnostic strategies in cervical carcinoma of an unknown primary (CUP). Eur Archives of Otorhinolaryngol. 2002;259:325-33. DOI: 10.1007/s00405-002-0470-1.Davis KS, Byrd JK, Mehta V, et al. Occult primary head and neck squamous cell carcinoma: utility of discovering primary lesions. Otolaryngology — Head and Neck Surgery. 2014;151(2):272-8. DOI: 10.1177/0194599814533494.Davis KS, Byrd JK, Mehta V, et al. Occult primary head and neck squamous cell carcinoma: utility of discovering primary lesions. Otolaryngology — Head and Neck Surgery. 2014;151(2):272-8. DOI: 10.1177/0194599814533494.Kwee T.C, Basu S, Cheng G, et al. FDG PET/CT in carcinoma of unknown primary. Eur J Nucl Med Mol Imaging. 2010;37:635-44. DOI: 10.1007/s00259-009-1295-6.Kwee T.C, Basu S, Cheng G, et al. FDG PET/CT in carcinoma of unknown primary. Eur J Nucl Med Mol Imaging. 2010;37:635-44. DOI: 10.1007/s00259-009-1295-6.Han A, Xue J, Hu M, et al. Clinical value of 18F-FDG PET-CT in detecting primary tumor for patients with carcinoma of unknown primary. Cancer Epidemiol. 2012;36(5):470-5. DOI: 10.1016/j.canep.2012.03.002.Han A, Xue J, Hu M, et al. Clinical value of 18F-FDG PET-CT in detecting primary tumor for patients with carcinoma of unknown primary. Cancer Epidemiol. 2012;36(5):470-5. DOI: 10.1016/j.canep.2012.03.002.Kitajima K, Nakajo M, Kaida H, et al. Present and future roles of FDG-PET/CT imaging in the management of gastrointestinal cancer: an update. Nagoya J Med Sci. 2017;79(4):527-43. DOI: 10.18999/nagjms.79.4.527.Kitajima K, Nakajo M, Kaida H, et al. Present and future roles of FDG-PET/CT imaging in the management of gastrointestinal cancer: an update. Nagoya J Med Sci. 2017;79(4):527-43. DOI: 10.18999/nagjms.79.4.527.Chen H, Pang Y, Wu J, et al. Comparison of [68Ga] Ga-DOTA-FAPI-04 and [18F] FDG PET/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer. Eur J Nucl Med Mol Imaging. 2020;47:1820-32. DOI: 10.1007/s00259-020-04769-z.Chen H, Pang Y, Wu J, et al. Comparison of [68Ga] Ga-DOTA-FAPI-04 and [18F] FDG PET/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer. Eur J Nucl Med Mol Imaging. 2020;47:1820-32. DOI: 10.1007/s00259-020-04769-z.Liu Q, Shi S, Liu S, et al. The added value of [68Ga] Ga-DOTA-FAPI-04 PET/CT in pancreatic cancer: a comparison to [18F] F-FDG. Eur Radiol. 2023;33:5007-16. DOI: 10.1007/s00330-023-09445-y.Liu Q, Shi S, Liu S, et al. The added value of [68Ga] Ga-DOTA-FAPI-04 PET/CT in pancreatic cancer: a comparison to [18F] F-FDG. Eur Radiol. 2023;33:5007-16. DOI: 10.1007/s00330-023-09445-y.Shu Q, Deng M, Hu M, et al. The additional role of [68Ga] Ga-FAPI-04 PET/CT in patients with unknown primary lesion with a negative or equivocal [18F] FDG. Eur J Nucl Med Mol Imaging. 2023;50:1442-52. DOI: 10.1007/s00259-022-06095-y.Shu Q, Deng M, Hu M, et al. The additional role of [68Ga] Ga-FAPI-04 PET/CT in patients with unknown primary lesion with a negative or equivocal [18F] FDG. Eur J Nucl Med Mol Imaging. 2023;50:1442-52. DOI: 10.1007/s00259-022-06095-y.Chen H, Zhao L, Ruan D, et al. Usefulness of [68Ga]Ga-DOTA-FAPI-04 PET/CT in patients presenting with inconclusive [18F]FDG PET/CT findings. Eur J Nucl Med Mol Imaging. 2021;48:73-86. DOI: 10.1007/s00259-020-04940-6.Chen H, Zhao L, Ruan D, et al. Usefulness of [68Ga]Ga-DOTA-FAPI-04 PET/CT in patients presenting with inconclusive [18F]FDG PET/CT findings. Eur J Nucl Med Mol Imaging. 2021;48:73-86. DOI: 10.1007/s00259-020-04940-6.Veldhuijzen van Zanten SEM, Pieterman KJ, Wijnhoven BPL, et al. FAPI PET versus FDG PET, CT or MRI for staging pancreatic-, gastric- and cholangiocarcinoma: systematic review and head-to-head comparisons of diagnostic performances. Diagnostics. 2022;12(8):1958. DOI: 10.3390/diagnostics12081958.Veldhuijzen van Zanten SEM, Pieterman KJ, Wijnhoven BPL, et al. FAPI PET versus FDG PET, CT or MRI for staging pancreatic-, gastric-and cholangiocarcinoma: systematic review and head-to-head comparisons of diagnostic performances. Diagnostics. 2022;12(8):1958. DOI: 10.3390/diagnostics12081958.Kömek H, Can C, Güzel Y, et al. 68Ga-FAPI-04 PET/CT, a new step in breast cancer imaging: a comparative pilot study with the 18F-FDG PET/CT. Ann Nucl Med. 2021; 35:744-52. DOI: 10.1007/s12149-021-01616-5.Kömek H, Can C, Güzel Y, et al. 68Ga-FAPI-04 PET/CT, a new step in breast cancer imaging: a comparative pilot study with the 18F-FDG PET/CT. Ann Nucl Med. 2021; 35:744-52. DOI: 10.1007/s12149-021-01616-5.Kumar R, Chauhan A, Zhuang H, et al. Clinicopathologic factors associated with false negative FDG-PET in primary breast cancer. Breast Cancer Res Treat. 2006;98:267-74. DOI: 10.1007/s10549-006-9159-2 .Kumar R, Chauhan A, Zhuang H, et al. Clinicopathologic factors associated with false negative FDG-PET in primary breast cancer. Breast Cancer Res Treat. 2006;98:267-74. DOI: 10.1007/s10549-006-9159-2 .Hamson E.J, Keane F.M, Tholen S, et al. Understanding fibroblast activation protein (FAP): substrates, activities, expression and targeting for cancer therapy. PROTEOMICS. Clinical Applications. 2014;8(5-6):454-63. DOI: 10.1002/prca.201300095.Hamson E.J, Keane F.M, Tholen S, et al. Understanding fibroblast activation protein (FAP): substrates, activities, expression and targeting for cancer therapy. PROTEOMICS. Clinical Applications. 2014;8(5-6):454-63. DOI: 10.1002/prca.201300095.

The authors declare that there are no conflicts of interest present.